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Abstract 
Objective: This systematic review examined the current literature, summarized research findings and identified 
research gaps regarding the efficacy of statins on audiological outcomes.  
Methods: Systematic search of electronic databases and grey literature was performed. Eligibility criteria was the 
study of a statin drug with report of audiological outcomes such as hearing, tinnitus, or balance in either human 
or animal studies. Data extraction and quality assessment were performed by two independently researchers. The 
characteristics of the study and research findings were collated and summarized. A narrative synthesis was 
conducted. Meta-analysis was not possible due to heterogeneity of the included studies. 
Results: Analysis of searches yielded 17 studies meeting the criteria. Included studies had variable drug type and 
dosage, outcome measures, and associated inner ear conditions. Most animal experiments showed promising 
audiological outcomes after statin treatment, demonstrated by the results of auditory brain stem response, 
distortion product otoacoustic emissions, and inner ear histology. However, no clear effect can be discerned in 
human trials due to the mixed results, and heterogeneity in research methodology and quality. Audiological 
outcomes were not always correlated with cholesterol levels.  
Conclusions: Statins remain a potential candidate as otoprotective agents which warrant further investigation.  
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Introduction  
Inner ear impairment can be characterized by cochlear dysfunction or vestibular dysfunction or both (1). 
Sensorineural hearing loss (SNHL) has a high prevalence and can cause significant adverse impact on an affected 
individual’s quality of life (2). The pathophysiological mechanisms involved in SNHL include vascular ischemia, 
oxidative stress, and inflammation (3). 
Hyperlipidemia has been reported to be associated with sudden sensorineural hearing loss (SSNHL) (4), and 
noise-induced hearing loss (NIHL) (5). One possible explanation regarding the mechanism of hearing damage by 
dyslipidemia involves vascular ischemia of the inner ear artery. Hyperlipidemia increases plasma viscosity (6) 
which can trigger the stenosis of the cochlear artery leading to cochlear ischemia and subsequent SNHL; therefore, 
vascular compromise is regarded as playing a vital role in SNHL (7). 
Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, commonly known as statins, are widely used as 
cholesterol-lowering drugs (8). Due to the strong evidence supporting cardiovascular benefits of its usage, statin 
therapy to reduce high cholesterol is recommended for people with cardiovascular risk factors. The overall 
benefits observed with statins appear to be greater than what might be expected from changes in lipid levels alone, 
suggesting effects beyond cholesterol reduction such as improved endothelial function and microcirculation, 
reduced oxidative stress, and decreased inflammation (9).  
The effect of statins, including the cholesterol lowering, anti-oxidative, and anti-inflammatory properties, could 
be beneficial as an otoprotective agent involving both hemodynamic and metabolic mechanisms. This is of interest 
because hearing loss associated with hyperlipidemia would be thereby potentially treatable. There has so far been 
little evidence to support their use in the treatment or prevention of inner ear dysfunction, hence statins are not 
routinely used for this purpose. This systematic review examined the current literature on the efficacy of statins 
on audiological outcomes. 
 
Method 
Identify relevant studies 
The following databases were searched: Medline, EMBASE, IPA (International Pharmaceutical Abstracts), and 
ClinicalTrials.gov. Grey literature was also sought through the conference abstracts searching on Google Scholar. 
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The steps followed the PRISMA guideline (10). Standardised terms and keywords were merged in the search for 
concepts of statin drugs and otoprotection. Study details were registered on PROSPERO (CRD42019133701). 
The search was limited to the English language because of resource constraints. The search strategies are reported 
in Appendix 1.  
Study selection 
Eligibility criteria for records to be included was the study of a statin with reporting of audiological outcomes 
such as hearing, tinnitus or balance in either human or animal studies. All study types were eligible except review 
articles and in vitro studies. Two screening steps were undertaken independently by two authors. The first step 
checked that each title and abstract was within the scope of research question. The second step considered the 
eligibility criteria. Discrepancies were resolved through discussion.  
Data extraction  
Data from each included study was extracted independently by two clinical experts on the team (PP, an 
otorhinolaryngologist and DB, an audiologist) using a data extraction form. Pre-specified data items included 
study design, participant demographics, sample size, drug type and dosage, and outcome evaluation. 
Discrepancies were identified and resolved through discussion.  
Quality assessment  
The reviewers independently assessed the methodological quality of the articles by applying the National 
Institutes of Health (NIH) Quality Assessment Tool. If the ratings were different, then reviewers discussed the 
article in an effort to reach consensus. The score was assigned for each item: ‘Yes’ was scored 1, and ‘No’ or 
‘Cannot determine’ or ‘Nor reported’ was scored 0. The summary score of each study was calculated, expressed 
as a percentage, and could range from 0% to 100%. These were categorized into four categories: poor (0–25%), 
fair (26–50%), good (51–75%) or excellent (76–100%). The quality score was not used as the criteria for eligibility 
because of the limited literature on this topic.  
Data synthesis 
A narrative synthesis was implemented for the present systematic review, as there were high heterogeneities of 
studies included. The characteristics of the study and research findings were collated and summarized.  
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Results 
A summary of the study selection processes with the reasons for exclusion is represented in Figure 1. Seventeen 
individual studies were included for data extraction. The results are presented in a narrative summary and review. 
We did not perform a meta-analysis as the studies were heterogeneous, and several of them were observational 
designs. 
Descriptions of included studies  
Nine articles revealed human studies comprising of 1 RCT (11), 3 pre-post studies (12-14), 2 cohort studies (15, 
16), 2 retrospective studies (17, 18), and 2 case reports (16, 19). Eight animal studies included 2 randomized 
studies (20, 21), and 6 non-randomized controlled interventional studies (22-27).  
Quality assessment 
The mean score on the NIH Quality Assessment Tool was 38% (range 7–79%). There were eight studies (47%) 
with fair quality; five studies (29%) had fair quality; three studies (18%) had good quality; and one study (6%) 
had excellent quality (See Table 1). 
Human studies 
Outcome measurements were highly variable among studies, and included audiometry (11-13, 15, 17-19), tinnitus 
questionnaire (11, 17), Tinnitus Handicap Questionnaire (THQ) (14), tinnitus degree/severity/loudness (13), self-
reports of tinnitus (19), and vertigo symptoms (16). The summary of characteristics and results of included human 
studies are demonstrated in Table 1.  
Two studies classified participants into responsive and unresponsive groups according to cholesterol levels after 
the treatment, and then compared the audiological outcomes (13, 14). The criteria for responsive and non-
responsive individuals were substantially different. Cholesterol responsive was defined by a return to normal 
cholesterol or triglyceride level but normal levels were not specified (13), or cholesterol level less than 200 mg/dL 
(14). 
Audiometry  
Mixed results were reported with 2 studies concluding no improvement in hearing threshold (11, 17), and 4 studies 
reporting some improvement (12, 13, 18, 19). Two studies reported a correlation between statin use and a reduced 
prevalence of hearing loss (15, 18). 
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There was no significant difference in pure tone thresholds between atorvastatin and placebo groups (11). Another 
study reported no significant difference in hearing threshold between simvastatin and ginkgo groups (17).  
Nine out of twelve (75%) patients with chronic-phase SSNHL had hearing improvement in at least 2 frequencies 
(12). There was a significant improvement of hearing threshold at higher frequencies in the cholesterol treatment 
responsive group compared to the unresponsive group (13). Patients on statins showed reduced severity of hearing 
loss than did non-statin users (18). A case report described a substantial hearing improvement after rosuvastatin 
therapy (19).  
Gopinath et al (15) indicated that persons with self-reported statin use had a 48% reduced odds of hearing loss. 
Another study reported reduced incidence of hearing loss compared with pretreatment audiograms in statin users 
relative to individuals who were not on a concurrent statin therapy (18).  
Tinnitus  
Studies described varied results of no significant improvement of tinnitus (11, 17), and significant improvement 
(13, 14, 19).  
There was a trend towards relief of tinnitus in the atorvastatin group while tinnitus severity scores were rather 
stable in the placebo group (11). In another study, there was no significant difference in tinnitus score between 
simvastatin and ginkgo groups (17).  
There was a significant improvement of tinnitus intensity and self-rated tinnitus in cholesterol responsive group 
relative to cholesterol non-responsive group (13). Improvement in THQ score by at least 10 points was seen in 
70.5% of patients in cholesterol responsive group compared to 4.2% in cholesterol unresponsive group (14). A 
case report described complete relief of tinnitus after statin therapy (19).  
Vertigo  
One article reported that 84% of vertiginous patients had complete resolution of vertigo and total remission in one 
case of recurrent vertigo after statin treatment (16).  
Cholesterol level and audiological outcomes 
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Most patients who received statin treatment had elevated cholesterol levels ranging from 100-190 (11) to 239-356 
(14) mg/dL. However, specified criteria of hyperlipidemia or cholesterol levels were not reported in some studies 
(13, 15, 16, 18). 
Successful cholesterol lowering was associated with significant improvement of tinnitus (13, 14) and hearing 
threshold (13). Another two studies also showed parallel results of cholesterol lowering and hearing improvement 
(12, 19). On the other hand, two studies reported no audiological improvement despite cholesterol reduction after 
statin treatment (11, 17).  
Animal experiments 
Outcome measurements were highly variable among studies, and include auditory brainstem response (ABR) (20-
22, 24-27), distortion product otoacoustic emissions (DPOAE) (21, 23, 24), and inner ear histology (20, 22, 25). 
The summary of characteristics and results of included animal studies are reported in Table 2. 
ABR  
Most of the included studies reported protection of hearing detected by ABR (20, 22, 24-27), except in one study 
(21).  
Cai et al (20) found that hearing thresholds remained stable at 40 dB in simvastatin-treated mice fed with high-
lipid diet while significant increased hearing thresholds from 35 dB to 60 dB was observed in the non-statin treated 
group. Three studies demonstrated the efficacy of statins to prevent NIHL (22, 26, 27). Park et al (22) revealed a 
significantly decreased hearing threshold shift of approximately 20 dB in the pravastatin-pretreated group of mice 
compared to the noise-only group at 1 and 14 days. ABR threshold after noise exposure was 5.83 dB in fluvastatin-
treated mice, which was substantially lower than the 41.7 dB in the noise-only group (27). Another study reported 
that fluvastatin given 7 days before noise exposure can protect the inner ear against NIHL in the guinea pigs (26). 
Statin treatment prior to acoustic injury appeared to be more effective than when given after noise exposure (26). 
Only one study examined statin treatment in cisplatin ototoxicity, reporting that ABR thresholds were significantly 
protected in cisplatin-treated mice receiving prior lovastatin relative to cisplatin-only treated mice (24). 
Furthermore, hearing preservation was observed in diabetic mice treated with atorvastatin but without detailed 
information (25).  
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In contrast, there were no significant differences in hearing thresholds between atorvastatin-treated mice and 
control mice, but all animals had normal hearing threshold (21). 
DPOAE  
Three studies reported DPOAE results: all showed positive auditory outcomes of statin usage (21, 23, 24). Two 
of three studies reported both ABR and DPOAE outcomes (21, 24). The results were concordant in one study 
which demonstrated the preservation of both ABR threshold and DPOAE in the lovastatin treated group (24). 
Conversely, another study demonstrated better results of DPOAE in atorvastatin treated mice though no 
significant differences in hearing thresholds detected by ABR (21). 
Inner ear histology  
Three studies reported histological findings of the inner ear in animals (20, 22, 25). After statin administration, 
there was preservation of the numbers and morphology of hair cells and spiral ganglions in hyperlipidemic mice 
(20), and spiral ganglia and stria vascularis in diabetic mice (25). Conservation of hair cells were also 
demonstrated after noise exposure (22).  
Cholesterol level and audiological outcomes 
Hearing improvements corresponded to the results of cholesterol lowering in two studies (20, 22), but not related 
to cholesterol level in one study reported (21). Nonetheless, cholesterol levels were not reported in five studies 
(23-27). 
Normal hearing findings, alongside lower cholesterol levels and much less severe atherosclerotic lesions in 
simvastatin-treated mice, support the role statin drugs play in the protection of hearing loss (20). Interestingly, the 
inner ear protection efficacy of statins was also found when cholesterol lowering effects were absent (21). 
 
Discussion 
Current literature regarding a potential otoprotective effect of statin drugs has high variability in drug type and 
dosage, outcome measures, and associated inner ear status. Most of the studies were classified to have fair or poor 
quality, and a significant portion of included studies retrieved from grey literature reported limited information. 
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Most animal experiments showed promising audiological results; however, no clear effect can be discerned from 
human trials. The differences between animal experiments and human studies are potentially due to the difference 
in species, equivalent drug dosage, and outcome measurements.  
Drug type, dosage, and timing of administration 
Statin type and dosage varied among studies. While, low dose atorvastatin used before exposure to noise can 
potentially prevent NIHL in rats, the effect was not observed in higher doses (23). Animal studies demonstrated 
a protective effect when the drug was administered before or during noise exposure but showed limited efficacy 
when given after noise exposure (22, 23, 26, 27). This could be explained by the pathophysiology of ROS 
production in that ROS is hard to overcome when it has occurred but prevention by diminishing the inflammatory 
process is more effective.  
Outcome measures  
Most of the animal experiments demonstrated favourable outcomes of ABR and DPOAE in statin-treated animals, 
supported by histological findings. The discrepancy between ABR and DPOAE results in Syka et al (21) can be 
explained by the different pathways and sensitivities of the tests. (28, 29). 
Tinnitus evaluation varied highly among studies using self-reported symptoms and standard questionnaires which 
emphasizes the difficulty of comparison between studies.  
Inner ear conditions  
Tentative evidence was identified to support an otoprotective effect of statin against NIHL caused by acoustic 
overstimulation (13, 22, 23, 26, 27), and cisplatin ototoxicity (24). Interestingly, one accepted mechanism shared 
by these conditions is related to overproduction of ROS (30), supporting the proposal of an anti-oxidative effect 
of statin treatment. Statin treatment in patients with other SNHL and tinnitus showed mixed results with no 
benefits (11, 17, 21), and some benefits (12-15, 20, 25). Despite these mixed results of statin treatment, some 
reversibility of hearing loss and tinnitus was demonstrated in the chronic phase (12-14, 19).  
Cholesterol level and audiological outcomes  
Six studies showed positive audiological outcomes accompanied by lower cholesterol levels (12-14, 19, 20, 22), 
indicating cholesterol dependent effects of statin on audiological outcomes. These studies support the 
pathophysiology of vascular ischemia associated with hypercholesterolemia which leads to oxygen reduction, 
overproduction of ROS and an inflammatory process causing eventually to apoptotic cell death.  
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In contrast, three studies reported no correlation of inner ear functions and cholesterol lowering outcomes after 
statin treatment (11, 17, 21), signifying that hearing outcome may not be associated with cholesterol levels. Syka 
et al (21) showed some efficacy of inner ear protection after statin treatment with no effects on cholesterol levels, 
supporting the pleiotropic (cholesterol-independent) effects of statins (9).  
No significant improvement of hearing thresholds and tinnitus were reported in two studies although they showed 
the successful cholesterol lowering effect of statins (11, 17). Olzowy et al (11) included only patients who had 
presbycusis with moderately elevated cholesterol levels and Canis et al (17) showed a relatively small change of 
cholesterol level. It is possible that patients with higher baseline cholesterol levels or who had a larger change of 
cholesterol level might have a pronounced benefit from statin treatment on cochlear functions. 
 
Limitations of the study  
Some limitations of the current review are that a significant portion of included studies reported limited 
information, and only publications in the English language were included; thus, language bias may have occurred. 
 
Conclusion  
Included studies had variable methodology and quality. Most animal experiments showed promising results; 
however, no clear effect was discerned from the results in human trials. Developing therapeutic strategies for the 
prevention of hearing loss using otoprotective drugs, is one of the major goals of current auditory research, and 
statins remain of interest in this regard.  
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Figure 1: Flow chart of stages of the study selection process 
 
Table 1: Summary data of human studies  
OD = once daily; NR = not reported; THQ = Tinnitus Handicap Questionnaire; SSNHL = Sudden sensorineural 
hearing loss 
 
Table 2: Summary data of animal experiments  
ABR = Auditory brainstem response; DPOAE = Distortion Product Otoacoustic Emission; IP = Intraperitoneal; 
NR = not reported  
 
Appendix 1: Search strategy  
 
Table 1: Summary data of human studies  
 
Study 
no. 
 
Title Sample 
size 
Study population Statin drug, dosage and 
duration 
Outcome measures 
 
Audiological outcomes 
1 Effect of atorvastatin on progression of 
sensorineural hearing loss and tinnitus in the 
elderly: results of a prospective, 
randomized, double-blind clinical trial (11) 
48 
 
 
 
Adults with 
presbycusis 
 
 
Atorvastatin 40 mg OD  - Audiometry 
- Tinnitus questionnaire  
 
 
- Mean deterioration of hearing threshold of all ears in all frequencies was 1.30 
dB in the atorvastatin and 1.07 dB in the placebo group. There was no 
significant difference between both groups. 
- Trend toward a reduction of tinnitus score but not significant. 
Atorvastatin group: 38.3 -> 34.8 -> 27.6 
Placebo group: 23.6 -> 24.8 -> 26.8 
2 Hearing improvement after therapy for 
hyperlipidemia in patients with chronic-
phase sudden deafness (12) 
12 
 
Adults with 
unilateral 
SSNHL  
Pravastatin  
for 90-519 days 
 
- Audiometry  
 
- Nine patients had hearing improvement (> 10 dB) in more than 1 frequency  
- Mean hearing level had improved significantly at 125, 250, 500 and 2000 Hz. 
 
3 Low-Cholesterol Diet and Antilipid Therapy 
in Managing Tinnitus and Hearing Loss in 
Patients with Noise-Induced Hearing Loss 
and Hyperlipidemia (13) 
42 
 
 
Adults with 
subjective 
tinnitus and 
hearing loss due 
to noise exposure 
 
Simvastatin 10-40 mg OD  
or  
Atorvastatin 10-80 mg OD  
for 1-2 years  
 
- Audiometry 
- Tinnitus degree (1-10) 
- Tinnitus severity  
- Tinnitus loudness  
 
Comparing cholesterol responsive (N=20) and unresponsive (N=22) groups 
- Significant improvement of hearing threshold at 4,000 and 8,000 Hz but no 
significant difference at 500, 1,000, and 2,000 Hz in responsive group.   
- Significant improvement of tinnitus degree and severity in responsive group.   
 
4 Atorvastatin in the management of tinnitus 
with hyperlipidemias (14) 
98 
 
Adults with 
tinnitus and 
SNHL at least 
one year 
Atorvastatin 40 mg OD  
for 8 weeks 
- THQ 
 
Comparing cholesterol responsive (N=51) and unresponsive (N=47) groups 
- Improvement in tinnitus score in the responsive group was seen in 36 (70.5%) 
patients and in 2 (4.2%) patients of the unresponsive group. 
 
5 Dietary intake of cholesterol is positively 
associated and use of cholesterol-lowering 
medication is negatively associated with 
prevalent age-related hearing loss (15) 
 
274 Adults with 
presbycusis   
Statins - Audiometry - Reduced odds of having impaired hearing among those reporting statin use in 
both cross-sectionally and longitudinally. 
- Persons self-reporting statin use were 48% less likely to have hearing loss 
after multivariable adjustment [OR = 0.52; 0.29–0.93]. 
 
6 Vestibular vertigo associated with 
hyperlipidemia: response to antilipidemic 
therapy (16) 
31 
1 
Adults with 
recurrent vertigo  
 
 
Lovastatin or Pravastatin  
20-40 mg/d  
- Vertigo symptoms  - 84% of patients in a cohort had complete resolution of vertigo. 
- Total remission of vertigo and did not recur in a case report.  
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Simvastatin and Ginkgo biloba in the 
treatment of subacute tinnitus: a 
retrospective study of 94 patients (17) 
 
94 
 
 
 
 
Adults with 
moderate to 
severe tinnitus  
Simvastatin 40 mg OD  
for 4 months 
- Audiometry 
- Tinnitus questionnaire  
- There was no significant difference in hearing thresholds between simvastatin 
and ginkgo groups 
- There was no significant improvement in tinnitus scores between both groups. 
Simvastatin group: 41.4 -> 37.3  
Ginkgo group: 44.7 -> 41 
8 Concurrent use of cholesterol lowering 
drugs may reduce the incidence of 
ototoxicity in cisplatin-treated patients (18) 
 
NR Adults received 
cisplatin 
chemotherapy 
Lovastatin  
 
- Audiometry - A reduced incidence and severity of cisplatin-induced hearing loss in statin 
users relative to individuals who were not on a concurrent statin therapy.  
9 Hearing loss due to familial 
hypercholesterolemia and statin treatment 
(19) 
 
1 An adult with 
SSNHL, tinnitus 
and positional 
vertigo 
 
Rosuvastatin 40 mg OD  
for 1 year  
 
- Audiometry 
- Tinnitus status 
- There was a substantial improvement of hearing test and complete regression 
of tinnitus.  
15 
 
 
OD = once daily; NR = not reported; THQ = Tinnitus Handicap Questionnaire; SSNHL = Sudden sensorineural 
hearing loss 
Table 2: Summary data of animal experiments  
 
Study 
no. 
Title Sample 
size 
Study animals Statin drug, dosage and 
duration 
Outcome measures 
 
Audiological outcomes 
1 Effects of simvastatin on plasma 
lipoproteins and hearing loss in 
apolipoprotein E gene-deficient mice (20) 
30  
 
Mice  
 
Simvastatin oral  
for 14 weeks 
 
 
- ABR at 0.3-3 kHz 
- Histology 
- Hearing thresholds remained stable at 40 dB in simvastatin-treated group and 
significant increased hearing thresholds from 35 dB to 60 dB in no statin treated 
group. 
- Preservation of hair cells and neurons in the spiral ganglion in simvastatin-
treated group. 
 
 
2 Atorvastatin slows down the deterioration of 
inner ear function with age in mice (21) 
 
50 
 
Mice  Atorvastatin oral  
10 mg/kg/day  
for 8 weeks 
 
- ABR at 0.3-10 kHz 
- DPOAE at 4-40 kHz 
 
- All animals had normal hearing thresholds.  
- No significant differences in hearing thresholds between atorvastatin-treated 
group and control group. 
- Larger amplitudes of DPOAE in atorvastatin treated wild type mice especially 
at high frequencies (19 to 27 kHz). 
 
3 Pravastatin attenuates noise-induced 
cochlear injury in mice (22) 
29 
 
 
Mice Pravastatin oral  
25 mg/kg/day  
for 5 days prior to noise 
exposure and/or 3 days after 
noise exposure 
- ABR at 16 and 32 kHz 
- Histology  
- Hearing thresholds were 43.2-47.4 dB in the noise-only group, and 23.8-27.4 
dB in the pravastatin-pretreated group at 1 day after noise exposure.  
- Hearing thresholds were 41.9-45.9 dB the noise-only group, and 21.5-23.8 dB 
in the pravastatin-pretreated group at 14 days after noise exposure. 
- No increased attenuation of threshold shift when pravastatin was further 
administered after noise exposure, compared with the pre-exposure group. 
- Increase hair cells survival rate in statin-treated group. 
 
4 The effect of atorvastatin on preventing 
noise-induced hearing loss: an experimental 
study (23) 
 
40  Rats Pretreatment atorvastatin 
oral 5, 25, and 50 
mg/kg/day  
for 14 days 
- DPAOE at 2-8 kHz 
 
 
- Response amplitude was significantly decreased at all frequencies 
immediately after exposure to noise in all studied groups. 
- The amplitude increased after 72 hours to a level higher than temporary 
threshold shift (TTS); this change was only significant in the group received 5 
mg/kg atorvastatin. 
 
5 Protective effects of concurrent statin use 
against ototoxicity in cisplatin-treated mice 
(24) 
 
NR Mice Lovastatin oral 40 or 60 
mg/kg/day prior to cisplatin 
for 2 weeks 
- ABR at 8-40 kHz  
- DPOAE at 8-40 kHz 
 
- ABR response thresholds in the low to mid frequencies were significantly 
protected. 
- DPOAE were preserved, though reduced. 
 
6 The effect of atorvastatin on hearing 
impairment in diabetic mice (25) 
 
40 
 
Mice  
 
Atorvastatin 20 mg/kg IP 
every other day for 4 weeks 
- ABR at 16 and 32 kHz 
- Histology 
 
- There was a preservation of hearing. 
- There was a preservation of spiral ganglion neurons and stria vascularis.  
 
7 Fluvastatin attenuates acoustic injury (26) NR Guinea pigs Fluvastatin 50 mM direct to 
Lt cochlea either 7 days 
before or after noise 
exposure 
 
- ABR  - Fluvastatin given 7 days before can protect against NIHL. 
- Fluvastatin given 7 days after noise exposure was not as effective, but did 
show a mild protection.  
 
8 Fluvastatin protects against high decibel 
noise induced hearing loss (27) 
24 Guinea pigs  
 
Fluvastatin direct to Lt 
cochlea at the same time as 
noise exposure 
 
- ABR - ABR threshold elevation after exposure was 41.7±12 dB in noise only group, 
and 5.83±10.7 dB for noise exposed fluvastatin treated group. 
 
ABR = Auditory brainstem response; DPOAE = Distortion Product Otoacoustic Emission; IP = Intraperitoneal; 
NR = not reported 
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